GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Wuhan Hiteck Biological Pharma Co Ltd (SZSE:300683) » Definitions » Equity-to-Asset

Wuhan Hiteck Biological Pharma Co (SZSE:300683) Equity-to-Asset : 0.83 (As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Wuhan Hiteck Biological Pharma Co Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Wuhan Hiteck Biological Pharma Co's Total Stockholders Equity for the quarter that ended in Jun. 2024 was ¥2,455.5 Mil. Wuhan Hiteck Biological Pharma Co's Total Assets for the quarter that ended in Jun. 2024 was ¥2,964.4 Mil. Therefore, Wuhan Hiteck Biological Pharma Co's Equity to Asset Ratio for the quarter that ended in Jun. 2024 was 0.83.

The historical rank and industry rank for Wuhan Hiteck Biological Pharma Co's Equity-to-Asset or its related term are showing as below:

SZSE:300683' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.67   Med: 0.83   Max: 0.9
Current: 0.83

During the past 11 years, the highest Equity to Asset Ratio of Wuhan Hiteck Biological Pharma Co was 0.90. The lowest was 0.67. And the median was 0.83.

SZSE:300683's Equity-to-Asset is ranked better than
85.74% of 1066 companies
in the Drug Manufacturers industry
Industry Median: 0.59 vs SZSE:300683: 0.83

Wuhan Hiteck Biological Pharma Co Equity-to-Asset Historical Data

The historical data trend for Wuhan Hiteck Biological Pharma Co's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuhan Hiteck Biological Pharma Co Equity-to-Asset Chart

Wuhan Hiteck Biological Pharma Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.81 0.78 0.86 0.85 0.83

Wuhan Hiteck Biological Pharma Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.88 0.88 0.83 0.83 0.83

Competitive Comparison of Wuhan Hiteck Biological Pharma Co's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Wuhan Hiteck Biological Pharma Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Wuhan Hiteck Biological Pharma Co's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Wuhan Hiteck Biological Pharma Co's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Wuhan Hiteck Biological Pharma Co's Equity-to-Asset falls into.



Wuhan Hiteck Biological Pharma Co Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Wuhan Hiteck Biological Pharma Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=2478.155/2971.251
=0.83

Wuhan Hiteck Biological Pharma Co's Equity to Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

Equity to Asset (Q: Jun. 2024 )=Total Stockholders Equity/Total Assets
=2455.529/2964.396
=0.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Wuhan Hiteck Biological Pharma Co  (SZSE:300683) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Wuhan Hiteck Biological Pharma Co Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Wuhan Hiteck Biological Pharma Co's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Wuhan Hiteck Biological Pharma Co Business Description

Traded in Other Exchanges
N/A
Address
Hite Science and Technology Park, Wuhan Economic and Technological Development Zone, Hubei Province, Wuhan, CHN, 430056
Wuhan Hiteck Biological Pharma Co Ltd is a biopharmaceutical manufacturing enterprise in China. The company is primarily engaged in the development, production and sale of biological products. Its product portfolio comprises rat nerve growth factor freeze-dried powder injection, injection of anti-hepatitis B transfer factor freeze-dried powder injection, thrombin and other chemicals. The company also has more than 20 kinds of products such as hepatitis B treatment drug op Heparin and hemostatic agent thrombin.
Executives
Yan Jie Director
Li Sheng Qiang Executives

Wuhan Hiteck Biological Pharma Co Headlines

No Headlines